- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr John Fox Discusses Financial Toxicity Associated With Multidrug Regimens for Multiple Myeloma
With an increase in the use of 3- and 4-drug regimens in multiple myeloma, providers are going to need to communicate the out-of-pocket costs when presenting treatment options so that patients can make an informed decision, explained John Fox, MD, MHA, vice president of Clinical Transformation at Spectrum Health.
With an increase in the use of 3- and 4-drug regimens in multiple myeloma, providers are going to need to communicate the out-of-pocket costs when presenting treatment options so that patients can make an informed decision, explained John Fox, MD, MHA, vice president of Clinical Transformation at Spectrum Health.
Transcript
With 3- and 4-drug regimens becoming more widely used in multiple myeloma, how it this impacting financial toxicity associated with the disease?
With those 3- and 4-drug regimens, patients are having more and more out-of-pocket (OOP) costs. Thankfully, most people have an OOP maximum in Medicare, especially on the Part D, or oral drug, side. So, understanding what those benefits are is critical, and as we’ve been talking about today, there’s a lack of comparative information around the relative benefits of 1 3-drug regimen versus another 3-drug regimen, and there are different OOP costs for those patients.
So, increasingly, we’re going to need to understand what those are and present those to patients at the same time we present the treatment options so they can make a decision. A physician who prescribes a regimen a patient can’t afford and doesn’t know about it in advance is not being an effective patient advocate.
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
ALL Disparities, Treatment Gaps: AYA Patients Face Unique Challenges
June 4th 2025Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) face significant survival disparities and unmet needs for effective third-line treatments, highlighting urgent care gaps.
Read More
